An Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Over a Four-year Follow up Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study
Latest Information Update: 08 Oct 2024
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics; Proof of concept
Most Recent Events
- 04 Oct 2024 Planned primary completion date changed from 1 Apr 2028 to 1 Jul 2028.
- 04 Oct 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Oct 2022 Planned End Date changed from 1 Dec 2027 to 1 Dec 2028.